On the stock market since 2018, it operates in the world of health and science. It has 2,457 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 14% a year on average.
The company sells $761.5M a year; the problem isn’t sales — it’s costs running above that number.
It pays out $0.31 per share each year — regular cash for whoever holds the stock.
A loss of $27.9M against $761.5M in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, DPHAY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DPHAY has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.